Duchenne Muscular Dystrophy Drugs

A Global Strategic Business Report

MCP11652

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

3018

EXECUTIVE POOL

5850

PRICE

543

EXPERT INPUTS

38

COMPANIES

97

DATA TABLES

220

PAGES

9

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (12125)

255

CXO

874

VICE PRESIDENT

6322

DIRECTOR

3507

MANAGER

1167

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Duchenne Muscular Dystrophy Drugs Market to Reach US$29.7 Billion by 2030

The global market for Duchenne Muscular Dystrophy Drugs estimated at US$4.4 Billion in the year 2024, is expected to reach US$29.7 Billion by 2030, growing at a CAGR of 37.7% over the analysis period 2024-2030. Hospital Pharmacies, one of the segments analyzed in the report, is expected to record a 35.9% CAGR and reach US$16.5 Billion by the end of the analysis period. Growth in the Drug Store & Retail Pharmacies segment is estimated at 40.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.8 Billion While China is Forecast to Grow at 43.6% CAGR

The Duchenne Muscular Dystrophy Drugs market in the U.S. is estimated at US$1.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.4 Billion by the year 2030 trailing a CAGR of 43.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 30.9% and 30.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 32.5% CAGR.

Global Duchenne Muscular Dystrophy Drugs Market - Key Trends & Drivers Summarized

What Is Duchenne Muscular Dystrophy and Its Impact?

Duchenne Muscular Dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration and weakness. It primarily affects boys, with symptoms typically appearing between the ages of two and five. The disease is caused by mutations in the dystrophin gene, which is essential for muscle function. Without dystrophin, muscle fibers are damaged and eventually replaced by fat and connective tissue. The progression of DMD leads to loss of ambulation, respiratory and cardiac complications, and significantly reduced life expectancy. The impact on patients and their families is profound, necessitating ongoing medical care and support.

How Are Treatment Approaches Evolving?

Treatment approaches for Duchenne Muscular Dystrophy are evolving rapidly, with advancements in genetic therapies, molecular drugs, and symptomatic treatments. Historically, corticosteroids have been the mainstay of DMD treatment, helping to slow muscle degeneration. However, recent years have seen significant progress in gene therapy and exon-skipping drugs, which aim to address the underlying genetic causes of DMD. These innovative therapies are designed to restore or replace the defective dystrophin gene, offering the potential for more effective and long-lasting treatment outcomes. Additionally, supportive therapies such as physical therapy, respiratory care, and cardiac management remain crucial for improving quality of life and managing disease complications.

What Role Do Clinical Trials and Regulatory Approvals Play?

Clinical trials and regulatory approvals are pivotal in the development and availability of new treatments for Duchenne Muscular Dystrophy. Rigorous clinical trials are essential for demonstrating the safety and efficacy of new therapies. These trials often involve multiple phases and require collaboration between researchers, healthcare providers, and patients. Regulatory bodies, such as the FDA and EMA, play a critical role in evaluating and approving new drugs, ensuring that they meet stringent safety and effectiveness standards. Accelerated approval pathways and orphan drug designations are often utilized to expedite the development of treatments for rare diseases like DMD, providing patients with earlier access to promising therapies.

What Factors Are Driving Market Growth?

The growth in the Duchenne Muscular Dystrophy drugs market is driven by several factors, including advancements in genetic research, increased funding and investment, and the rising prevalence of the disease. Technological innovations in gene editing and molecular biology are paving the way for more targeted and effective treatments. Increased funding from governments, non-profit organizations, and pharmaceutical companies is accelerating research and development efforts. The rising awareness and diagnosis of DMD are also contributing to market growth, as more patients seek treatment. Additionally, collaborations between biotech firms and academic institutions are fostering the development of innovative therapies. The regulatory environment, with initiatives to fast-track the approval of orphan drugs, is further supporting market expansion, providing hope for improved outcomes for patients with DMD.

SCOPE OF STUDY

The report analyzes the Duchenne Muscular Dystrophy Drugs market by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Exon Skipping, Steroid Therapy, Mutation Suppression, Other Segments).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World..

SELECT PLAYERS

FibroGen, Inc.; ITALFARMACO S.p.A.; NS Pharma Inc.; PTC Therapeutics, Inc.; Sarepta Therapeutics, Inc.; Satellos Bioscience, Inc.

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

A Prelude to Duchenne Muscular Dystrophy

Global Economic Update

Tariff Impact on Global Supply Chain Patterns

Competition

Product Development as Hallmark of Global Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy Drugs – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 38 Players Worldwide in 2025 (E)

Global Market Overview and Prospects

Global Duchenne Muscular Dystrophy Drugs Market Set for a Rapid Growth, Driven by Rising Prevalence

A Review of the Approved DMD Drugs

North America and Europe to Remain Lucrative Markets

Molecular Therapy, Hospital/Clinic & Hospital Pharmacy: Hale & Hearty Segments of Duchenne Muscular Dystrophy Market

Dynamic Factors Keeping Duchenne Muscular Dystrophy Market Growing

Market Drivers

Market Restraints & Challenges

Market Opportunities

Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising R&D Investment to Boost DMD Market

EXHIBIT: Select Therapy Candidates Under Development for Treating DMD

Growing Government Support Propels Market Expansion

Biologics - The Most Dynamic Segment of the Market

Blossoming of Gene Therapy in Duchenne Muscular Dystrophy Treatment Domain

Gene Therapy for DMD Treatment

Elevidys, The First Ground-breaking Gene Therapy for Treatment of Duchenne Muscular Dystrophy (DMD)

Children’s National Hospital Starts Offering Newly Approved Gene Therapy for DMD

Promising Gene Therapies

Potential Side-Effects & Risks of Gene Therapies

Vamorolon Holds Potential to Lessen Health Risks Linked with Extended Use of Steriods

DT-DEC01 Offers Promise to Stabilize or Improve Motor Function

AOC 1044 Receives Orphan Drug Status for DMD44

Italfarmaco Group Announces NDA Acceptance for Givinostat Targeting Duchenne Muscular Dystrophy

Uptrend in Healthcare Expenditure Creates Substantial Opportunities

4. GLOBAL MARKET PERSPECTIVE

World Recent Past, Current & Future Analysis for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Exon Skipping by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Exon Skipping by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Analysis for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Steroid Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Steroid Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Other Therapeutic Approaches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Other Therapeutic Approaches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Analysis for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Drug Store & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Drug Store & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2018, 2025 & 2030

World Duchenne Muscular Dystrophy Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2018 through 2030

World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2018, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

USA Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

USA 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Canada 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

JAPAN

Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Japan 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

CHINA

China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

China Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

China 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

EUROPE

Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2018, 2025 & 2030

FRANCE

France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

France Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

France 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

GERMANY

Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Germany 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Italy 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

UNITED KINGDOM

UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

UK Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

UK 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Rest of Europe 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

ASIA-PACIFIC

Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Asia-Pacific 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

REST OF WORLD

Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Exon Skipping, Steroid Therapy and Other Therapeutic Approaches Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Therapeutic Approach - Percentage Breakdown of Value Sales for Exon Skipping, Steroid Therapy and Other Therapeutic Approaches for the Years 2018, 2025 & 2030

Rest of World Recent Past, Current & Future Analysis for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of World Historic Review for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2023 and % CAGR

Rest of World 12-Year Perspective for Duchenne Muscular Dystrophy Drugs by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Store & Retail Pharmacies and Online Pharmacies for the Years 2018, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *
AAVogen, Inc.	%
Akashi Therapeutics, Inc.	%
ARMGO Pharma, Inc.	%
Athena Diagnostics, Inc.	%
Avidity Biosciences	%
Beech Tree Labs	%
Bioleaders Corp.	%
BioMarin Pharmaceutical, Inc.	%
Biophytis	%
Capricor Therapeutics, Inc.	%

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll